Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TELO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTelomir announces peer-reviewed preclinical study showing drug reduced liver injury in disease model
Filed May 20, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
medium
Telomir-1 reduced oxidative stress, liver copper buildup, and injury markers in a zebrafish model of Wilson's disease, a genetic disorder causing toxic copper accumulation in organs.
Press Release, May 20, 2026 view on EDGAR → -
medium
Study published in peer-reviewed journal Advances in Redox Research, providing independent scientific validation of the company's lead drug candidate in preclinical testing.
Press Release, May 20, 2026 view on EDGAR → -
medium
Drug improved survival outcomes and locomotor performance in the animal model, suggesting potential therapeutic benefit beyond just biochemical markers.
Press Release, May 20, 2026 view on EDGAR →
Summary
Telomir Pharmaceuticals disclosed publication of a peer-reviewed preclinical study evaluating its lead drug candidate, Telomir-1, in a zebrafish model of Wilson's disease. The study, published in Advances in Redox Research, showed the drug reduced multiple disease markers including oxidative stress, abnormal calcium signaling, liver copper accumulation, and liver injury biomarkers.
Animals treated with Telomir-1 also showed improved survival and movement compared to untreated controls. For retail investors, this represents scientific validation in an independent academic publication, which can strengthen the drug's development profile. However, zebrafish and cellular models are very early-stage research—most drugs that work in animal models fail in human trials.
Wilson's disease is a rare genetic disorder, so even if successful, the commercial market would be limited. Watch for any announcements about advancing Telomir-1 into human clinical trials or partnerships with larger pharmaceutical companies that could fund further development. The company will need significant capital to move from preclinical research to FDA-approved therapy.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 20, 2026, Telomir Pharmaceuticals, Inc. issued a press release announcing publication of a peer-reviewed preclinical study titled “Intracellular copper redox modulation disrupts ROS–Ca²⁺ amplification in an ATP7B-deficient zebrafish model of Wilson’s disease” in the journal Advances in Redox Research.
The company disclosed publication of a peer-reviewed preclinical study in a scientific journal. The study evaluated Telomir-1 in a zebrafish model of Wilson's disease, a genetic disorder causing copper accumulation. This represents scientific validation of the company's drug candidate in an academic publication.
Added in current filing · verify on EDGAR →
The publication reported preclinical findings evaluating Telomir-1 (Telomir-Zn) in cellular systems and a zebrafish model of Wilson’s disease, including findings demonstrating reductions in oxidative stress signaling, intracellular calcium dysregulation, hepatic copper accumulation, liver injury biomarkers, histopathological degeneration, and improvements in locomotor performance and survival outcomes.
The study showed Telomir-1 reduced multiple disease markers in the Wilson's disease model including oxidative stress, calcium dysregulation, liver copper accumulation, and liver injury biomarkers. The drug also improved locomotor performance and survival outcomes. These are positive preclinical efficacy signals, though zebrafish and cellular models are early-stage research and do not guarantee human clinical success.
Event · Item 9.01 — Financial Statements and Exhibits
Telomir Pharmaceuticals filed an 8-K attaching a press release dated May 20, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
99.1 Press Release dated May 20, 2026
The company attached a press release dated May 20, 2026 as Exhibit 99.1. The 8-K body does not disclose the content or subject matter of the press release, so the nature and materiality of the announcement cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify